Journal of Hematology & Oncology,
Journal Year:
2024,
Volume and Issue:
17(1)
Published: June 24, 2024
Abstract
Significant
advances
have
been
made
in
chimeric
antigen
receptor
T
(CAR-T)-cell
therapy
for
the
treatment
of
recurrent
or
refractory
B-cell
hematologic
malignancies.
However,
CAR-T-cell
has
not
yet
achieved
comparable
success
management
aggressive
T-cell
This
article
reviews
challenges
treating
malignancies
and
summarizes
progress
preclinical
clinical
studies
this
area.
We
present
an
analysis
trials
therapies
grouped
by
target
classification.
Moreover,
review
focuses
on
major
encountered
therapies,
including
nonspecific
killing
due
to
sharing
contamination
with
cell
products
during
preparation.
discusses
strategies
overcome
these
challenges,
presenting
novel
therapeutic
approaches
that
could
enhance
efficacy
applicability
These
ideas
provide
important
information
future
promote
further
development
application
field.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: June 19, 2024
Chimeric
antigen
receptor
(CAR)
T-cell
therapy
has
proven
a
breakthrough
in
cancer
treatment
the
last
decade,
giving
unprecedented
results
against
hematological
malignancies.
All
approved
CAR
products,
as
well
many
being
assessed
clinical
trials,
are
generated
using
viral
vectors
to
deploy
exogenous
genetic
material
into
T-cells.
Viral
have
long-standing
history
gene
delivery,
and
thus
underwent
iterations
of
optimization
improve
their
efficiency
safety.
Nonetheless,
capacity
integrate
semi-randomly
host
genome
makes
them
potentially
oncogenic
via
insertional
mutagenesis
dysregulation
key
cellular
genes.
Secondary
cancers
following
administration
appear
be
rare
adverse
event.
However
several
cases
documented
few
years
put
spotlight
on
this
issue,
which
might
been
underestimated
so
far,
given
relatively
recent
deployment
therapies.
Furthermore,
initial
successes
obtained
malignancies
not
yet
replicated
solid
tumors.
It
is
now
clear
that
further
enhancements
needed
allow
T-cells
increase
long-term
persistence,
overcome
exhaustion
cope
with
immunosuppressive
tumor
microenvironment.
To
aim,
variety
genomic
engineering
strategies
under
evaluation,
most
relying
CRISPR/Cas9
or
other
editing
technologies.
These
approaches
liable
introduce
unintended,
irreversible
alterations
product
cells.
In
first
part
review,
we
will
discuss
non-viral
used
for
generation
T-cells,
whereas
second
focus
non-gene
engineering,
particular
regard
advantages,
limitations,
Finally,
critically
analyze
different
combinations,
delineating
superior
safety
profile
production
next-generation
T-cell.
Human Vaccines & Immunotherapeutics,
Journal Year:
2024,
Volume and Issue:
20(1)
Published: July 3, 2024
Recently,
CAR-T
cell
therapy
in
hematological
malignancies
has
received
extensive
attention.
The
objective
of
this
study
is
to
gain
a
comprehensive
understanding
the
current
research
status,
development
trends,
hotspots,
and
emerging
topics
pertaining
cells
treatment
malignancies.
Articles
for
from
years
2012
2023
were
obtained
assessed
Web
Science
Core
Collection
(WoSCC).
A
bibliometric
approach
was
employed
conduct
scientific,
comprehensive,
quantitative
analysis,
as
well
visual
particular
domain.
analysis
conducted
on
corpus
3643
articles,
which
collaboratively
authored
by
72
countries
various
institutions.
treating
shows
an
increasing
trend
each
year.
Notably,
identified
institutions
displaying
highest
level
activity,
journals
with
most
citations
output,
authors
who
garnered
frequency
co-citations.
Furthermore,
successfully
hotspots
highlighted
six
within
This
exploration
about
2023.
findings
will
serve
valuable
reference
guide
researchers
seeking
delve
deeper
into
field
determine
future
direction
their
research.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Nov. 8, 2024
Optimizing
cancer
treatment
has
become
a
pivotal
goal
in
modern
oncology,
with
advancements
immunotherapy
and
genetic
engineering
offering
promising
avenues.
CAR-T
cell
therapy,
revolutionary
approach
that
harnesses
the
body's
own
immune
cells
to
target
destroy
cells,
shown
remarkable
success,
particularly
treating
acute
lymphoblastic
leukemia
(ALL),
other
hematologic
malignancies.
While
therapy
promise,
challenges
such
as
high
cost
manufacturing
complexity
remain.
However,
its
efficacy
solid
tumors
remains
limited.
The
integration
of
CRISPR/Cas9
technology,
powerful
precise
genome-editing
tool,
also
raises
safety
concerns
regarding
unintended
edits
off-target
effects,
offers
synergistic
potential
overcome
these
limitations.
can
enhance
by
improving
specificity
persistence
reducing
resistance
tumor-induced
immunosuppression.
This
combination
facilitate
knockout
checkpoint
inhibitors,
boosting
anti-tumor
activity
cells.
Recent
studies
have
demonstrated
CRISPR/Cas9-edited
previously
untreatable
types,
new
hope
for
patients
refractory
cancers.
not
only
enhances
but
paves
way
personalized
therapies
tailored
individual
profiles.
review
highlights
ongoing
research
efforts
refine
this
explores
revolutionize
across
broader
range
As
progresses,
holds
promise
transforming
treatment,
making
it
more
effective
accessible.
current
advancements,
challenges,
future
prospects
innovative
therapeutic
strategy.
Molecular Therapy,
Journal Year:
2024,
Volume and Issue:
32(9), P. 2856 - 2891
Published: Aug. 5, 2024
T
cell-redirecting
therapies
(TCRTs),
such
as
chimeric
antigen
receptor
(CAR)
or
cell
(TCR)
cells
and
engagers,
have
emerged
a
highly
effective
treatment
modality,
particularly
in
the
B
plasma
cell-malignancy
setting.
However,
many
patients
fail
to
achieve
deep
durable
responses;
while
lack
of
truly
unique
tumor
antigens,
concurrent
on-target/off-tumor
toxicities,
hindered
development
TCRTs
for
other
cancers.
In
this
review,
we
discuss
recent
developments
TCRT
targets
hematological
malignancies,
well
novel
targeting
strategies
that
aim
address
these,
other,
challenges.
Theoretical and Natural Science,
Journal Year:
2025,
Volume and Issue:
89(1), P. 52 - 56
Published: Jan. 15, 2025
Using
gene
editing
techniques,
cancer
treatments
are
being
transformed
into
new
ones
that
precisely
alter
genetic
patterns.
The
usefulness,
difficulties,
and
future
potential
of
HDR,
Base
Editing,
Prime
Editing
assessed
in
this
review.
While
HDR
provides
accurate
repair,
its
specificity
efficiency
not
as
strong.
base
shows
promise
correcting
flaws,
it
must
be
used
with
caution
to
reduce
unintended
consequences.
A
technique
called
makes
more
secure
possible
without
rupturing
DNA.
Despite
their
huge
potential,
advancement
areas
like
security,
ethics,
efficacy
distribution
is
crucial.
article
examines
these
techniques'
for
treating
by
compiling
research
on
them.
Highlights in Science Engineering and Technology,
Journal Year:
2025,
Volume and Issue:
129, P. 57 - 66
Published: March 3, 2025
Cancer
has
been
one
of
the
primary
causes
lethality
worldwide,
driving
demand
for
innovative
treatments
alongside
traditional
methods
like
surgery,
chemotherapy
and
radiotherapy.
Advances
in
immunotherapy,
particularly
with
antibody-drug
conjugators
(ADCs)
genetically
modified
immune
cells,
such
as
CAR-T
TCR-T
are
bringing
goal
defeating
cancer
closer
to
reality.
ADCs
enable
precise
delivery
cytotoxic
drugs
cells
while
sparing
healthy
tissue;
engineered
enhance
targeting
against
tumours.
However,
these
therapies
still
need
overcome
challenges,
including
side
effects,
production
complexity,
high
costs.
A
synergistic
approach
that
combines
can
solve
problem
tumour
heterogeneity
drug
resistance.
This
dual-targeting
strategy
amplifies
cell
by
combining
ADC-induced
cytotoxicity
a
sustained
response
from
cells.
In
addition,
early
clinical
trials
have
demonstrated
this
combination
therapy,
especially
drug-resistant
cancers,
improves
patient
survival
reduces
recurrence
rates.
Although
synergetic
therapy
is
facing
problems
regarding
immune-related
effects
accessibility,
integration
effectively
enhances
which
personalised,
long-lasting,
effective.
